PDF下载 ( 1865 KB)
肝源性糖尿病发病机制的最新进展
DOI: 10.3969/j.issn.1001-5256.2021.02.038
作者贡献声明:胡晗负责撰写论文及文献收集；田彩云、张国远负责提出建议；林世德负责拟定写作思路，指导撰写文章并最后定稿。
Latest advances in the pathogenesis of hepatogenous diabetes
-
摘要: 肝源性糖尿病(HD)是终末期肝病的常见并发症，对患者预后的不良影响已得到大量研究证实。近十年国内外对HD的发病机制进行了大量研究，取得了一些进展。系统综述了HD的发病机制研究进展，为临床医生的诊断与治疗HD提供参考。Abstract: Hepatogenous diabetes (HD) is a common complication of end-stage liver disease, and many studies have confirmed its adverse effect on prognosis. In recent ten years, a great number of studies have been conducted on the pathogenesis of HD and some progress has been made. This article reviews the research advances in the pathogenesis of HD, in order to provide a reference for the diagnosis and treatment of HD by clinicians.
-
Key words:
- Liver Cirrhosis /
- Hepatogenous Diabetes /
- Insulin Resistance
-
[1] ORSI E, GRANCINI V, MENINI S, et al. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?[J]. Liver Int, 2017, 37(7): 950-962. DOI: 10.1111/liv.13337 [2] GARCÍA-COMPEÁN D, GONZÁLEZ-GONZÁLEZ JA, LAVALLE-GONZÁLEZ FJ, et al. Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?[J]. World J Gastroenterol, 2016, 22(10): 2869-2874. DOI: 10.3748/wjg.v22.i10.2869 [3] KUMAR R. Hepatogenous diabetes: An underestimated problem of liver cirrhosis[J]. Indian J Endocrinol Metab, 2018, 22(4): 552-559. DOI: 10.4103/ijem.IJEM_79_18 [4] LIU L, JIANG YY, LIU J. Glucose metabolism and insulin secretion in patients with chronic hepatitis B cirrhosis of different Child-Pugh grades and their association with inflammatory response[J]. J Clin Hepatol, 2020, 36(2): 324-328. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.018刘丽, 江颖仪, 刘景. 不同Child-Pugh分级慢性乙型肝炎肝硬化患者糖代谢、胰岛素分泌情况及其与炎症反应的相关性分析[J]. 临床肝胆病杂志, 2020, 36(2): 324-328. DOI: 10.3969/j.issn.1001-5256.2020.02.018 [5] GRANCINI V, TROMBETTA M, LUNATI ME, et al. Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease[J]. J Hepatol, 2015, 63(6): 1484-1490. DOI: 10.1016/j.jhep.2015.08.011 [6] NISHIDA T, TSUJI S, TSUJⅡ M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis[J]. Am J Gastroenterol, 2006, 101(1): 70-75. DOI: 10.1111/j.1572-0241.2005.00307.x [7] MVLLER MJ, PIRLICH M, BALKS HJ, et al. Glucose intolerance in liver cirrhosis: Role of hepatic and non-hepatic influences[J]. Eur J Clin Chem Clin Biochem, 1994, 32(10): 749-758. [8] GRANCINI V, TROMBETTA M, LUNATI ME, et al. Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients[J]. J Hepatol, 2019, 70(5): 954-962. DOI: 10.1016/j.jhep.2019.01.015 [9] OKITA K, IWAHASHI H, KOZAWA J, et al. Usefulness of the insulin tolerance test in patients with type 2 diabetes receiving insulin therapy[J]. J Diabetes Investig, 2014, 5(3): 305-312. DOI: 10.1111/jdi.12143 [10] PERSEGHIN G, MAZZAFERRO V, SERENI LP, et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation[J]. Hepatology, 2000, 31(3): 694-703. DOI: 10.1002/hep.510310320 [11] KAWAGUCHI T, TANIGUCHI E, ITOU M, et al. Insulin resistance and chronic liver disease[J]. World J Hepatol, 2011, 3(5): 99-107. DOI: 10.4254/wjh.v3.i5.99 [12] ZHAO Y, XING H, WANG X, et al. Management of diabetes mellitus in patients with chronic liver diseases[J]. J Diabetes Res, 2019, 2019: 6430486. [13] HONG YS, CHANG Y, RYU S, et al. Hepatitis B and C virus infection and diabetes mellitus: A cohort study[J]. Sci Rep, 2017, 7(1): 4606. DOI: 10.1038/s41598-017-04206-6 [14] WANG H, GOU W, SUN FB, et al. Clinical value of GADA in patients with hepatitis B cirrhosis and hepatogeous diabetes[J]. Chin J Clin Gastroenterol, 2019, 31(5): 319-323. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-LCXH201905017.htm王贺, 苟卫, 孙风波, 等. 谷氨酸脱羧酶抗体在乙肝肝硬化并肝源性糖尿病患者中的临床应用价值[J]. 临床消化病杂志, 2019, 31(5): 319-323. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXH201905017.htm [15] ANDRES J, BARROS M, ARUTUNIAN M, et al. Treatment of hepatitis C virus and long-term effect on glycemic control[J]. J Manag Care Spec Pharm, 2020, 26(6): 775-781. [16] SINGHAL A, AGRAWAL A, LING J. Regulation of insulin resistance and type Ⅱ diabetes by hepatitis C virus infection: A driver function of circulating miRNAs[J]. J Cell Mol Med, 2018, 22(4): 2071-2085. DOI: 10.1111/jcmm.13553 [17] WANG CC, CHENG PN, KAO JH. Systematic review: Chronic viral hepatitis and metabolic derangement[J]. Aliment Pharmacol Ther, 2020, 51(2): 216-230. DOI: 10.1111/apt.15575 [18] CHEN J, WANG F, ZHOU Y, et al. Chronic hepatitis C virus infection impairs insulin secretion by regulation of p38δ MAPK-dependent exocytosis in pancreatic β-cells[J]. Clin Sci (Lond), 2020, 134(5): 529-542. DOI: 10.1042/CS20190900 [19] CAI C, ZENG J, WU H, et al. Association between hepatitis B virus infection and diabetes mellitus: A meta-analysis[J]. Exp Ther Med, 2015, 10(2): 693-698. DOI: 10.3892/etm.2015.2537 [20] HUANG YW, WANG TC, LIN SC, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: A nationwide cohort study[J]. Clin Infect Dis, 2013, 57(12): 1695-1702. DOI: 10.1093/cid/cit603 [21] CHRISTEN V, TREVES S, DUONG FH, et al. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A[J]. Hepatology, 2007, 46(2): 558-565. DOI: 10.1002/hep.21611 [22] THALER FS, BANGOL B, BILJECKI M, et al. Possible link of genetic variants to autoimmunity in GAD-antibody-associated neurological disorders[J]. J Neurol Sci, 2020, 413: 116860. DOI: 10.1016/j.jns.2020.116860 [23] NISHIMURA A, MATSUMURA K, KIKUNO S, et al. Slowly Progressive type 1 diabetes mellitus: Current knowledge and future perspectives[J]. Diabetes Metab Syndr Obes, 2019, 12: 2461-2477. DOI: 10.2147/DMSO.S191007 [24] KUMAR K, MEHERSHAHI S, CHIME C, et al. Glycogen hepatopathy: A rare and underrecognized cause of recurrent transaminitis in patients with uncontrolled type 2 diabetes mellitus[J]. Case Rep Gastroenterol, 2018, 12(2): 466-472. DOI: 10.1159/000492205 [25] LI HF, LIU K, ZHANG H. Changes and clinical significance of serum glutamate decarboxylase antibodies and insulin concentration in patients with hepatogenic diabetes[J]. J Clin Exp Med, 2019, 18(14): 1513-1516. (in Chinese) DOI: 10.3969/j.issn.1671-4695.2019.14.016李会芳, 刘岢, 张辉. 肝源性糖尿病患者血清谷氨酸脱羧酶抗体、胰岛素浓度的变化及其临床意义[J]. 临床和实验医学杂志, 2019, 18(14): 1513-1516. DOI: 10.3969/j.issn.1671-4695.2019.14.016 [26] ELKRIEF L, RAUTOU PE, SARIN S, et al. Diabetes mellitus in patients with cirrhosis: Clinical implications and management[J]. Liver Int, 2016, 36(7): 936-948. DOI: 10.1111/liv.13115 [27] LI X, YAO QY, LIU HC, et al. Placental growth factor silencing ameliorates liver fibrosis and angiogenesis and inhibits activation of hepatic stellate cells in a murine model of chronic liver disease[J]. J Cell Mol Med, 2017, 21(10): 2370-2385. DOI: 10.1111/jcmm.13158 [28] NOVO E, BOCCA C, FOGLIA B, et al. Liver fibrogenesis: Un update on established and emerging basic concepts[J]. Arch Biochem Biophys, 2020, 689: 108445. DOI: 10.1016/j.abb.2020.108445 [29] VLASSARA H, URIBARRI J. Advanced glycation end products (AGE) and diabetes: Cause, effect, or both?[J]. Curr Diab Rep, 2014, 14(1): 453. DOI: 10.1007/s11892-013-0453-1 [30] SEBEKOVÁ K, KUPCOVÁ V, SCHINZEL R, et al. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation[J]. J Hepatol, 2002, 36(1): 66-71. DOI: 10.1016/S0168-8278(01)00232-X [31] PACKER M. Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance[J]. Circulation, 2020, 141(25): 2095-2105. DOI: 10.1161/CIRCULATIONAHA.119.045561 [32] KIETZMANN T. Liver zonation in health and disease: Hypoxia and hypoxia-inducible transcription factors as concert masters[J]. Int J Mol Sci, 2019, 20(9): 2347. DOI: 10.3390/ijms20092347 [33] SATO Y, TSUYAMA T, SATO C, et al. Hypoxia reduces HNF4α/MODY1 protein expression in pancreatic β-cells by activating AMP-activated protein kinase[J]. J Biol Chem, 2017, 292(21): 8716-8728. DOI: 10.1074/jbc.M116.767574 [34] NATH B, SZABO G. Hypoxia and hypoxia inducible factors: Diverse roles in liver diseases[J]. Hepatology, 2012, 55(2): 622-633. DOI: 10.1002/hep.25497 [35] YI P, PARK JS, MELTON DA. Betatrophin: A hormone that controls pancreatic β cell proliferation[J]. Cell, 2013, 153(4): 747-758. DOI: 10.1016/j.cell.2013.04.008 [36] ARIAS-LOSTE MT, GARCÍA-UNZUETA MT, LLERENA S, et al. Plasma betatrophin levels in patients with liver cirrhosis[J]. World J Gastroenterol, 2015, 21(37): 10662-10668. DOI: 10.3748/wjg.v21.i37.10662 [37] LI S, LIU D, LI L, et al. Circulating betatrophin in patients with type 2 diabetes: A Meta-analysis[J]. J Diabetes Res, 2016, 2016: 6194750. [38] ABU-FARHA M, ABUBAKER J, TUOMILEHTO J. ANGPTL8 (betatrophin) role in diabetes and metabolic diseases[J]. Diabetes Metab Res Rev, 2017, 33(8): 19-29. [39] LEE SH, RHEE M, KWON HS, et al. Serum betatrophin concentrations and the risk of incident diabetes: A nested case-control study from chungju metabolic disease cohort[J]. Diabetes Metab J, 2018, 42(1): 53-62. DOI: 10.4093/dmj.2018.42.1.53 [40] HU H, SUN W, YU S, et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients[J]. Diabetes Care, 2014, 37(10): 2718-2722. DOI: 10.2337/dc14-0602 [41] CHRISTENSEN AS, HÆDERSDAL S, STORGAARD H, et al. GIP and GLP-1 potentiate sulfonylurea-induced insulin secretion in hepatocyte nuclear factor 1α mutation carriers[J]. Diabetes, 2020, 69(9): 1989-2002. DOI: 10.2337/db20-0074 [42] ITOU M, KAWAGUCHI T, TANIGUCHI E, et al. Dipeptidyl peptidase-4: A key player in chronic liver disease[J]. World J Gastroenterol, 2013, 19(15): 2298-2306. DOI: 10.3748/wjg.v19.i15.2298 [43] ASO Y, KATO K, SAKURAI S, et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease[J]. Int J Clin Pract, 2019, 73(5): e13335. DOI: 10.1111/ijcp.13335 [44] DEACON CF. Corrigendum: Physiology and pharmacology of DPP-4 in Glucose homeostasis and the treatment of type 2 diabetes[J]. Front Endocrinol (Lausanne), 2019, 10: 275. DOI: 10.3389/fendo.2019.00275 [45] BERINGER A, MIOSSEC P. IL-17 and TNF-α co-operation contributes to the proinflammatory response of hepatic stellate cells[J]. Clin Exp Immunol, 2019, 198(1): 111-120. DOI: 10.1111/cei.13316 [46] BUECHLER C, HABERL EM, REIN-FISCHBOECK L, et al. Adipokines in liver cirrhosis[J]. Int J Mol Sci, 2017, 18(7) : 1392. DOI: 10.3390/ijms18071392 [47] BOUTARI C, TZIOMALOS K, ATHYROS VG. The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease[J]. Hippokratia, 2016, 20(4): 259-263. [48] ARAI Y, KAMIDE K, HIROSE N. Adipokines and aging: Findings from centenarians and the very old[J]. Front Endocrinol (Lausanne), 2019, 10: 142. DOI: 10.3389/fendo.2019.00142 [49] MOUSA N, ABDEL-RAZIK A, SHETA T, et al. Serum leptin and homeostasis model assessment-IR as novel predictors of early liver fibrosis in chronic hepatitis B virus infection[J]. Br J Biomed Sci, 2018, 75(4): 192-196. DOI: 10.1080/09674845.2018.1505187 [50] GUO Y, LIU L, WANG J. Adiponectin and the risk of new-onset atrial fibrillation: A meta-analysis of prospective cohort studies[J]. Biosci Rep, 2019, 39(6): BSR20182284. DOI: 10.1042/BSR20182284 -
本文二维码
计量
- 文章访问数: 814
- HTML全文浏览量: 113
- PDF下载量: 105
- 被引次数: 0
下载:
